Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gremubamab
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Gremubamab is a first-in-class, bivalent, bispecific human immunoglobulin G1 kappa monoclonal antibody designed to target *Pseudomonas aeruginosa* infections. It selectively binds to two key virulence factors of *P. aeruginosa*: the PcrV protein (a component of the type III secretion system involved in host cell cytotoxicity) and the Psl exopolysaccharide (involved in bacterial colonization and tissue adherence). By targeting both these antigens, gremubamab aims to enhance neutrophil-mediated killing of *P. aeruginosa* and prevent associated cytotoxicity. The drug was developed primarily for prevention and treatment of nosocomial pneumonia (including ventilator-associated pneumonia) and bronchiectasis with chronic or high-risk *Pseudomonas* infection. Clinical development included phase 1 and phase 2 trials; however, further development for nosocomial pneumonia was discontinued due to safety/efficacy reasons.
- Other names
- Anti-Psl/PcrV
02
Targets
PcrV (Type III secretion protein PcrV)Psl (Pseudomonas aeruginosa Psl exopolysaccharide)
Beyond the preview
Go deeper on gremubamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gremubamab.